A Prospective Study Assessing Tumour Response, Survival, and Palliative Care Outcomes in Patients with HIV-Related Kaposi's Sarcoma at Queen Elizabeth Central Hospital, Blantyre, Malawi
- PMID: 22496970
- PMCID: PMC3310220
- DOI: 10.1155/2012/312564
A Prospective Study Assessing Tumour Response, Survival, and Palliative Care Outcomes in Patients with HIV-Related Kaposi's Sarcoma at Queen Elizabeth Central Hospital, Blantyre, Malawi
Abstract
Background. Human-Immunodeficiency-Virus- (HIV-) related Kaposi's sarcoma (KS) has a high prevalence in Africa; however, there is minimal published data on treatment and outcomes in this population. Objective and Design. This was a prospective study of 50 patients, aiming to assess the impact of vincristine therapy on tumour response and survival and to assess palliative care outcomes in patients with HIV-related KS. Methods. 50 consecutive patients were recruited during 2008. Vincristine therapy and highly active antiretroviral therapy (HAART) were given. Tumour response, survival, and chemotherapy-related toxicities were documented. Palliative care outcomes were assessed using the African Palliative Care Association (APCA) Palliative Outcome Scale (POS). Results. The majority of patients were male, and the median age was 33 years. At baseline assessment, the median CD4 T-cell count was 263, and 50% patients had evidence of peripheral neuropathy. The overall response rate was 64% at 6 weeks, and median progression-free survival was 30 weeks. Treatment was generally well tolerated, with peripheral neuropathy the main dose-limiting toxicity. Conclusion. The combination of vincristine and HAART is feasible and effective in a low resource setting, although peripheral neuropathy is a dose-limiting factor. This patient group carries a high mortality and as such adequate access to palliative care is crucial.
Figures




Similar articles
-
Burden, characteristics, management and outcomes of HIV-infected patients with Kaposi's sarcoma in Zomba, Malawi.Public Health Action. 2013 Jun 21;3(2):180-5. doi: 10.5588/pha.13.0003. Public Health Action. 2013. PMID: 26393024 Free PMC article.
-
Kaposi's sarcoma in children: an open randomised trial of vincristine, oral etoposide and a combination of vincristine and bleomycin.Eur J Cancer. 2014 May;50(8):1472-81. doi: 10.1016/j.ejca.2014.02.019. Epub 2014 Mar 14. Eur J Cancer. 2014. PMID: 24636877 Clinical Trial.
-
The effect of HAART in 254 consecutive patients with AIDS-related Kaposi's sarcoma.AIDS. 2009 Aug 24;23(13):1701-6. doi: 10.1097/QAD.0b013e32832d080d. AIDS. 2009. PMID: 19550283 Clinical Trial.
-
A risk and benefit assessment of treatment for AIDS-related Kaposi's sarcoma.Drug Saf. 1999 May;20(5):403-25. doi: 10.2165/00002018-199920050-00002. Drug Saf. 1999. PMID: 10348092 Review.
-
Kaposi's sarcoma: a reevaluation.Recent Results Cancer Res. 1995;139:275-96. Recent Results Cancer Res. 1995. PMID: 7541146 Review.
Cited by
-
Burden, characteristics, management and outcomes of HIV-infected patients with Kaposi's sarcoma in Zomba, Malawi.Public Health Action. 2013 Jun 21;3(2):180-5. doi: 10.5588/pha.13.0003. Public Health Action. 2013. PMID: 26393024 Free PMC article.
-
Treatment outcomes of AIDS-associated Kaposi's sarcoma under a routine antiretroviral therapy program in Lilongwe, Malawi: bleomycin/vincristine compared to vincristine monotherapy.PLoS One. 2014 Mar 14;9(3):e91020. doi: 10.1371/journal.pone.0091020. eCollection 2014. PLoS One. 2014. PMID: 24632813 Free PMC article.
-
Trends in Kaposi's sarcoma-associated Herpesvirus antibodies prior to the development of HIV-associated Kaposi's sarcoma: a nested case-control study.Int J Cancer. 2015 Jun 15;136(12):2822-30. doi: 10.1002/ijc.29329. Epub 2014 Nov 28. Int J Cancer. 2015. PMID: 25395177 Free PMC article.
-
Characteristics and Treatment Response of Patients with HIV Associated Kaposi's Sarcoma in Central Kenya.HIV AIDS (Auckl). 2022 Apr 25;14:207-215. doi: 10.2147/HIV.S359278. eCollection 2022. HIV AIDS (Auckl). 2022. PMID: 38808105 Free PMC article.
References
-
- Banda LT, Parkin DM, Dzamalala CP, Liomba NG. Cancer incidence in Blantyre, Malawi 1994–1998. Tropical Medicine and International Health. 2001;6(4):296–304. - PubMed
-
- Grulich AE, Li Y, McDonald AM, Correll PK, Law MG, Kaldor JM. Decreasing rates of Kaposi’s sarcoma and non-Hodgkin’s lymphoma in the era of potent combination antiretroviral therapy. AIDS. 2001;15(5):629–633. - PubMed
-
- Engels EA, Pfeiffer RM, Goedert JJ, et al. Trends in cancer risk among people with AIDS in the United States 1980–2002. AIDS. 2006;20(12):1645–1654. - PubMed
-
- Makombe SD, Harries AD, Yu JKL, et al. Outcomes of patients with Kaposi’s sarcomawho start antiretroviral therapy under routine programme conditions in Malawi. Tropical Doctor. 2008;38(1):5–7. - PubMed
-
- Malawi GO. Malawi HIV and AIDS Monitoring and Evaluation Report: 2008-2009. Lilongwe, Malawi: 2008.
LinkOut - more resources
Full Text Sources
Research Materials